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Longitudinal studiesRecent developments of PET amyloid ligands have made it possible to visualize the presence of Aβ deposition
in the brain of living participants and to assess the consequences especially in individuals with no objective
sign of cognitive deficits. The present review will focus on amyloid imaging in cognitively normal elderly,
asymptomatic at-risk populations, and individuals with subjective cognitive decline. It will cover the preva-
lence of amyloid-positive cases amongst cognitively normal elderly, the influence of risk factors for AD, the
relationships to cognition, atrophy and prognosis, longitudinal amyloid imaging and ethical aspects related
to amyloid imaging in cognitively normal individuals. Almost ten years of research have led to a few consen-
sual and relatively consistent findings: some cognitively normal elderly have Aβ deposition in their brain, the
prevalence of amyloid-positive cases increases in at-risk populations, the prognosis for these individuals is
worse than for those with no Aβ deposition, and significant increase in Aβ deposition over time is detectable
in cognitively normal elderly. More inconsistent findings are still under debate; these include the relationship
between Aβ deposition and cognition and brain volume, the sequence and cause-to-effect relations between
the different AD biomarkers, and the individual outcome associated with an amyloid positive versus negative
scan. Preclinical amyloid imaging also raises important ethical issues. While amyloid imaging is definitely
useful to understand the role of Aβ in early stages, to define at-risk populations for research or for clinical
trial, and to assess the effects of anti-amyloid treatments, we are not ready yet to translate research results
into clinical practice and policy. More researches are needed to determine which information to disclose
from an individual amyloid imaging scan, the way of disclosing such information and the impact on individ-
uals and on society.
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This review will focus on amyloid imaging in cognitively normal el-
derly, asymptomatic at-risk populations, and individuals with subjec-
tive cognitive decline. It is one of two side-to-side review papers, the
second one by Vandenberghe (2013–this issue) focusing on amyloid
imaging in cognitively impaired populations. The present effort extends
from a talk presented at the Alzheimer's Association International Con-
ference (http://www.alz.org/aaic/overview.asp) in July 2012 on amy-
loid imaging in preclinical individuals. It will cover the prevalence of
amyloid-positive cases amongst cognitively normal elderly, the influ-
ence of risk factors for AD, the relationships to cognition, atrophy and
prognosis, longitudinal amyloid imaging and ethical aspects related to
amyloid imaging in cognitively normal individuals. The goal was not to
be exhaustive but to give weighted opinions on most challenging con-
temporary debates based on our current state of knowledge. Thus,
some topics will not be covered, such as the relationships with other
brain imaging modalities (e.g. fluoro-deoxyglucose (FDG)-PET,
task-related and resting-state functional MRI, diffusion tensor imaging)
and cerebrospinal fluid (CSF) biomarkers, or discussion on the similari-
ties and differences between the various PET amyloid ligands.
β-amyloid (Aβ) deposition is one of the main hallmarks of
Alzheimer's disease and is thought to play a central role in the neurode-
generative process characterizing this disease (Hardy and Selkoe, 2002;
Masters et al., 2006). Neuropathological studies have shownmore than
20 years ago that substantial level of Aβ deposition can be found in the
autopsied brain of cases with documented normal cognition (Braak and
Braak, 1997; Crystal et al., 1988; Katzman et al., 1988; Price and Morris,
1999). Recently, PET amyloid ligands have been developed, the first one
(except from FDDNP see below) being the 11C-Pittsburgh Compound B
(11C-PIB) PET ligand (Klunk et al., 2004), followed by the recently FoodTable 1
Examples of the prevalence of amyloid-positive cases by clinical group. This illustrates the
derly (CNE) according to studies, probably due to variability in the methods and in the s
(MCI) and patients with Alzheimer's disease (AD) is also provided for the sake of comparis
References Amyloid ligand CNE
n
(Rowe et al., 2010) PIB 177
(Jagust et al., 2010) PIB 19
(Mormino et al., 2012)a PIB 75
(Okello et al., 2009) PIB 26
(Lowe et al., 2009) PIB 20
(Jack et al., 2008) PIB 20
(Koivunen et al., 2011) PIB 13
(Mintun et al., 2006)a PIB 20
(Fleisher et al., 2011)a Florbetapir 82
(Rodrigue et al., 2012) Florbetapir 87
(Sperling et al., 2013)a Florbetapir 78
(Doraiswamy et al., 2012) Florbetapir 69
(Villemagne et al., 2011) Florbetaben 32
(Vandenberghe et al., 2010) Flutemetamol 15
a Studies that used different methods to define the threshold for amyloid-positivity, th
amyloid-positive cases within the clinical group.and Drug Administration (FDA)-approved 18F-florbetapir (Choi et al.,
2009;Wong et al., 2010) and other 18F-labeled ligands (Herholz and
Ebmeier, 2011). Thanks to these developments, we entered a new
exciting area where it is possible to visualize plaques in the brain
of living participants. This offers the unique opportunity to get fur-
ther – including longitudinal – information in these individuals, so
as to improve our understanding of the consequence of the pres-
ence of Aβ deposition in the brain of cognitively normal elderly,
and more generally of the role of Aβ deposition in early AD patho-
logical processes. Note that studies will be reviewed in what follows
irrespective of the PET amyloid ligand being used, with the exception
of studies using FDDNP (e.g. Small et al., 2006) that will not be included
here as we aimed at specifically addressing issues related to Aβ while
FDDNP binds to both Aβ and tau abnormalities.
2. The presence of Aβ in the brain of cognitively normal elderly
and at-risk populations
2.1. The prevalence of amyloid-positive cases within cognitively normal
elderly
Consistent with neuropathological studies (Price and Morris,
1999), neuroimaging amyloid-PET studies found amyloid-positive
cases within cognitively normal (“healthy”) older people. The first
in-vivo 11C-PIB PET study reported one 11C-PIB-positive case amongst
the control elderly (Klunk et al., 2004), and this has been consistently
reported since then. A bimodal distribution of neocortical 11C-PIB
values is usually reported within elderly subjects with normal cogni-
tion (e.g. Klunk, 2011), though there is recent and accumulating ev-
idence for intermediate cases (see below). A majority of healthy
elderly shows low 11C-PIB retention, but part of them shows distinctlyvariability in the percentage of amyloid-positive cases amongst cognitively normal el-
amples (see text for details). The prevalence in patients with mild cognitive elderly
on.
MCI AD
% Aβ + n % Aβ + n % Aβ +
33% 57 68% 53 98%
47% 65 72% 19 89%
15–35% – – 10 90%
0% 31 55% - -
30% 23 40% 13 100%
30% 17 53% 8 100%
15% 29 72% – –
10–20% – – 10 90%
21–28% 60 40–47% 68 81–85%
20% – – – –
14–23% – – – –
14% 51 37% 31 68%
16% 20 60% 30 97%
7% 20 50% 27 93%
us leading to different proportions of amyloid-positive cases; % Aβ +: percentage of
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loads in AD patients, especially the posterior cingulate cortex –
precuneus and the anterior cingulate cortex –medial orbitofronal cor-
tex (Aizenstein et al., 2008; Archer et al., 2006; Bourgeat et al., 2010;
Dickerson et al., 2009; Hatashita and Yamasaki, 2010; Jack et al., 2008;
Mintun et al., 2006; Morris et al., 2010; Nelissen et al., 2007; Price and
Morris, 1999; Rowe et al., 2007; Storandt et al., 2009).While neuropath-
ological and amyloid-PET neuroimaging studies have thus consistently
demonstrated that some elderly with normal cognition may have Aβ
deposition in their brain, what is less consensual is the prevalence of
cognitively normal elderly with an amyloid-positive scan. Extreme-
ly variable proportions have been reported in the literacy ranging from
0% (Okello et al., 2009) to 47% (Jagust et al., 2010), with prevalence of
10 to 30% being more frequently reported (Quigley et al., 2011) (see
Table 1 for examples). Several factors are likely to explain this consider-
able variability. This could reflect methodological differences across
studies (e.g. the amyloid ligand or themethod used to define a positivity
threshold), or genuine differences due to the samples and reflecting dif-
ferences in the screening process or in genetic, social, ethnical and envi-
ronmental factors (see “The influence of at-risk factors” below).
Actually, the particular PET amyloid ligand that is used is probably
not the main element to account for this large variability, as several
studies reported a very good correlation between the different PET
amyloid ligands (Johnson et al., 2013; Vandenberghe et al., 2010;
Villemagne et al., 2012) (see also the side article by Vandenberghe et
al. 2013–in this issue, for further details). By contrast, the method
used to define positivity probably accounts for a significant part of this
variability. They are clearly negative and clearly positive cases but
there are also intermediate cases (Fig. 1). As further discussed below,
these intermediate cases represent a non-negligible proportion of the
cognitively normal elderly and their classification as positive or nega-
tive is highly sensitive to the method, which will thus significantly im-
pact on the proportion of amyloid-positive scans. Note that not much
is known about these intermediate cases, and this would be an impor-
tant topic for future research. One previous work showed that interme-
diate cortical PIB values seem to reflect both lower number of elevated
PIB regions and lower PIB value in these regions, through in the same
network, as compared to the clearly positive cases (Mormino et al.,Fig. 1. Illustration of positive, negative, and intermediate caseswithin the cognitively normal el
represents the mean neocortical 18F-florbetapir SUVR from an individual. The majority (67%)
value is within 2SD of the controls younger than 60 years = HC b 60 yrs). Three cases were
the iterative outlier approach). There were 25% of intermediate cases, i.e. cases classified as po2012). However, further studies are needed, notably longitudinal
studies to follow the progression of amyloid deposition in these inter-
mediate individuals as well as to assess their risk of conversion as com-
pared to the positive and negative categories.
There are many methodological factors that may influence the
classification of cases (see Edison et al., 2011 for example): the
method used to read the scan (either through visual inspection or
using quantitative values), the regions that are considered, the
values that are used, e.g. corrected from partial volume effects or
not, scaled using the pons or the cerebellum or another region,
etc. It has been proposed for example that the pons may be more
suitable as a reference region in specific cases, e.g. for longitudinal
studies (Villain et al., 2012) or when amyloid deposition may be
present in the cerebellum (e.g., in early-onset familial AD) (Edison
et al., 2012; Fleisher et al., 2012). Another determining factor is
the method used to define the threshold from which a scan is clas-
sified as positive or negative. Numerous methods have been used
in the literature: clustering analyses, the 95th percentile, the itera-
tive outlier approach, an absolute cut-off (e.g. SUVR > 1.50), the
mean + 2 standard deviation (SD) of healthy elderly controls, and
the mean + 2SD of healthy young controls (supposedly devoid of
Aβ deposition), for a non-exhaustive list. The study by Mormino et
al. (2012) is a good illustration of this point, as it showed that
when using two different methods to define the threshold (i.e. the
iterative outlier approach versus the mean + 2SD of young healthy
controls), the percentage of 11C-PIB-positive individuals amongst
healthy elderly varied considerably (from 15 to 35%) (see also
Aizenstein et al., 2008). In the IMAP project conducted in the Inserm
U1077 Unit in Caen (France), 3 out of 36 (8%) cognitively normal el-
derly were clearly positive (i.e. showed Aβ load in the range of AD
patients). Only these 3 cases were classified as amyloid-positive
using the iterative outlier approach (Fig. 1), while 9 additional
cases were classified positively when using a group of 12 participants
younger than 55 yrs (under the assumption that these individuals
have no Aβ deposition and therefore the corresponding PET signal
should only reflect noise). As a whole, intermediate cases can be as
frequent as 20–25% in cognitively normal elderly populations and
they may be responsible for a large part of the variability in thederly. These data are issued from the IMAP study (InsermU1077, Caen, France). Each circle
of healthy controls older than 60 years (HC > 60 yrs) is clearly negative (i.e. their SUVR
clearly positive (i.e. classified as positive both compared to younger controls and using
sitive or negative according to the method.
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reason for differences in the proportion of amyloid-positive elderly:
the screening procedure and selection criteria used in the different
studies probably also account for a large part of this variability. Sev-
eral factors are known to influence the proportion of amyloid-
positive cases as discussed in the following section, and these factors
may be more or less represented or controlled for according to the
studies.
2.2. The effects of age and ApoE4
The two main risk factors for AD, namely age and ApoE4, have been
consistently shown to have a significant impact on Aβ deposition in
normal elderly (Mielke et al., 2012). For example, the prevalence of
amyloid-positive cases within healthy older participants raised from
18% in the seventh decade to 60% in those over 80 yrs (Rowe et al.,
2010) or from 0% at ages 45–49 yrs to 30% in the eighth decade in an-
other study (Morris et al., 2010). Note that a linear relationship was
found between Aβ deposition and age evenwithin the 11C-PIB-negative
cases when assessing a wide age range (23–80 years) (Vandenberghe
et al., 2010). Similarly, amongst cognitively normal elderly, 49% of
ApoE4 carriers were
11
C-PIB-positive while they were only 21% within
the non-carriers (Rowe et al., 2010). This effect is reported in many
studies and is found to be dose-dependent and region-specific, i.e. to
be more pronounced in some brain regions (such as temporo-parietal
areas) than in others (Morris et al., 2010; Fleisher et al., 2013;
Kantarci et al., 2012; Reiman et al., 2009; Villemagne et al., 2011). Age
and ApoE are likely to account for part of the variability in the propor-
tion of amyloid-positive cases as there are great differences between
some studies/samples (e.g. 43% ApoE4 in Rowe et al., 2010 versus 22%
in Doraiswamy et al., 2012, and a mean age of 69.8 years old in Rowe
et al., 2010 versus 78 years old in Jagust et al., 2010).
2.3. Individuals with subjective cognitive decline
Individuals with subjective cognitive decline are elderly who
present with a cognitive complaint but do not show any significant
cognitive deficit compared to subjects their age. This is a rather
broad definition that may refer to many different entities as consen-
sual criteria for subjective cognitive decline are missing to date. The
presence or not of individuals with subjective cognitive decline is
another factor that may influence the proportion of amyloid-
positive cases in elderly cohorts as this criteria is not always con-
trolled for. Thus, Perrotin et al. (2012) showed increased proportion
of 11C-PIB positive cases amongst elderly who consider that their
memory is the same or worse relative to people their age, compared
to those who think their memory is better. A relationship between a
subjective memory complaints composite score and cortical PiB
binding has also been reported (Amariglio et al., 2012), but other re-
ports found no significant difference in global neocortical 11C-PIB
between healthy elderly with and without subjective cognitive de-
cline (Chételat et al., 2010a). The significance of the effect thus likely
depends on the cohort and the method to determine amyloid-
positivity (see above) as well as to assess subjective cognitive decline.
The different risk-factors may also interact, as suggested for example
by the finding that subjective cognitive decline was only associated
with elevated 11C-PIB binding in ApoE4 carriers (Rowe et al., 2010).
2.4. The effects of other genetic and environmental factors
A familial, and especially maternal, history of AD has also been
reported to be associated with increased 11C-PIB SUVR (Mosconi
et al., 2010). This effect was shown to be independent from that of
ApoE4 (Xiong et al., 2011), suggesting that non-APOE susceptibility
genes for AD influence AD biomarkers. In the same line, a very inter-
esting study by Scheinin et al. (2011) assessing cognitively preservedmonozygotic and dizygotic cotwins of persons with AD showed that
cognitively normal dizygotic cotwins had normal low 11C-PIB SUVR,
while the monozygotic cognitively normal cotwins had abnormally
elevated SUVR, almost at the level of their AD cotwins. This suggests
that genetic factors at least partly determine the development of Aβ
plaques, but also that there may be environmental/acquired factors
that modulate the relationship between brain amyloidosis and cog-
nition. This view agrees with studies highlighting the effect of educa-
tion (Rentz et al., 2010), lifetime cognitive engagement (Landau
et al., 2012), and physical exercise (Head et al., 2012; Liang et al.,
2010) on 11C-PIB deposition or on its association to cognition or neu-
ronal injury. In the same line, ApoE4 carriers who engaged in moder-
ate levels of exercise had a lower amyloid burden than ApoE4
carriers with lower levels of exercise and this effect of exercise was
not seen in the noncarriers (Head et al., 2012). While the effects of
these different factors are not clear-cut, with some discrepancies be-
tween studies, they overall indicate that, consistent with the reserve
theory (Stern, 2002), higher reserve proxies are associated with re-
duced amyloidosis or Aβ-related cognitive or neuronal deficits.
2.5. Asymptomaticmutation carriers for the early-onset familial form of AD
Finally, further insights in this question arise from studies on the
early onset familial formof AD (EOFAD). Thus, studies conducted in car-
riers of mutations that lead to EOFAD showed that increased amyloid
load can be detected at a presymptomatic stage (Klunk et al., 2007;
Knight et al., 2011; Villemagne et al., 2009). Interestingly, the topo-
graphical pattern is slightly different from that observed in sporadic
AD (Fig. 2), with a predominance of Aβ deposition in the striatum of
asymptomatic EOFAD while the neocortex is less systematically and
less significantly involved than in sporadic AD, independently of muta-
tion type (Klunk et al., 2007; Knight et al., 2011; Villemagne et al., 2009)
(see Rinne and Någren, 2010; Berti et al., 2011 for reviews). Increased
11C-PIB binding has also been reported in the thalamus and the cerebel-
lum in asymptomatic EOFAD (Knight et al., 2011; Villemagne et al.,
2009).
As for the timing and sequence of the apparition of brain Aβ de-
position, a recent publication in EOFAD showed that Aβ deposition
can be detected 15 years before expected symptom onset –
corresponding to the parental age at onset as determined by a
semistructured interview in which family members were asked
about the age of first progressive cognitive decline (Bateman
et al., 2012). This was also true for increased CSF tau and brain
atrophy, while changes in CSF Aβ-42 were detected 25 years be-
fore, and hypometabolism and memory deficits 10 years before
expected symptom onset. This is a very informative study from
the Dominantly Inherited Alzheimer Network (DIAN) collaborative
study gathering the largest MRI and PET multicentre database on
this population. These findings were confirmed and extended in
two other studies from a large Columbian kindred suggesting that
neurodegenerative changes could precede or at least accompany
evidence of Aβ deposition (Fleisher et al., 2012; Reiman et al.,
2012). These results are crucial as they question the prevailing am-
yloid hypothesis and current models of the dynamic and sequence
of the different biomarkers (Craig-Schapiro et al., 2009; Frisoni et
al., 2010; Jack et al., 2010; Petersen, 2010; Weiner et al., 2010)
that predict that Aβ deposition occurs first and is responsible for
neurodegeneration. However, generalization to the common sporadic
form of AD from results obtained in familial AD should be considered
with caution. Results from comparable studies in preclinical sporadic
AD (such as the ADNI or AIBL cohorts) and others, are still warranted
to determine the sequence and timing of biomarkers in sporadic AD
(see also below).
Altogether, many genetic risk factors involved in familial or spo-
radic AD were found to influence Aβ deposition, suggesting that Aβ
load is highly heritable (Berti et al., 2011). However, healthy life
Fig. 2. Illustration of the brain distribution of 18F-florbetapir in six cases from the IMAP project (Inserm U1077, Caen, France). The figure shows disproportionate binding of
18F-florbetapir in the caudate nucleus in the asymptomatic and symptomatic mutation carriers for the early-onset familial form of AD compared to both sporadic AD cases and
amyloid-positive cognitively normal elderly.
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position in the brain and/or its effect on brain integrity and cognition.
3. Relation to clinical status, cognitive performances and
brain volume
3.1. Relation to concomitant cognition and brain volume
There have been quite numerous studies assessing the relation to
cognition, even specifically within normal elderly, but the results re-
main overall puzzling: there are almost as many studies showing no
significant relationships (Aizenstein et al., 2008; Marchant et al.,
2012; Mormino et al., 2009; Resnick and Sojkova, 2011; Resnick et
al., 2010; Sperling et al., 2009; Storandt et al., 2009; Storandt et al.,
2012) as those showing a significant effect, and in the latter the rela-
tionship was rarely strong and general but rather modest and/or
concerned a specific population with diverging results according to
studies (Chételat et al., 2011; Kantarci et al., 2012; Mormino et al.,
2009; Oh et al., in press; Oh et al., 2012; Pike et al., 2007; Rentz et
al., 2011; Rodrigue et al., 2012). For example, relationships are usually
reported with episodic memory deficits, but a study also reported a
link with processing speed and working but not episodic memory
(Rodrigue et al., 2012). Moreover, discrepant results have been
reported in a same study with two CNE samples from two different
databases (Mormino et al., 2009), and significant relationships have
been observed only within females (Pike et al., 2011), non-ApoE4 car-
riers (Pike et al., 2011), or mainly in ApoE4 carriers (Kantarci et al.,
2012) or low educated cognitively normal elderly (Rentz et al.,
2010). In another study from the AIBL cohort, the relationships with
episodic memory were found to concern only inferior temporal Aβ
deposition (Chételat et al., 2011), or only normal elderly with subjec-
tive cognitive decline (Chételat et al., 2010a). Note that in the same
cohort from the AIBL study, cognitively normal elderly without sub-
jective cognitive decline showed a reverse relationship with higher
memory performances in 11C-PIB-positive compared to 11C-PIB-
negative cases (Chételat et al., 2010b). Similar findings have been
reported in a previous preliminary study (Aizenstein et al., 2008).
These 11C-PIB-positive “super-performers” also had larger temporallobe, which suggests that they represent a particularly resistant sub-
sample with larger brain reserve (Chételat et al., 2010b) (see also
above for the effect of education and brain reserve).
By contrast, in normal elderly with subjective memory decline, a
relation was observed in the more expected direction with increased
atrophy as amyloid load increases (Chételat et al., 2010a). In this
study, the relationship was assessed voxel-to-voxel and local correla-
tions were found in individuals with subjective cognitive decline
within the posterior cingulate cortex and medial frontal area, which
are the regions of highest Aβ deposition. There was no relationship
within the hippocampus where atrophy predominates in AD,
suggesting that atrophy is not due to local Aβ in this structure but in-
volves other neuropathological processes. Distant (temporal) Aβ de-
position for example has been found to be related to hippocampal
atrophy (Bourgeat et al., 2010), and additional, partly independent,
processes are thought to be involved (Chételat et al., 2011; La Joie
et al., 2012). Neurofibrillary tangles are very likely to be implicated
as these lesions develop very early in the hippocampus and they are
known to correlate to neuronal loss and atrophy. When assessed in
healthy elderly independently from whether or not they have subjec-
tive cognitive decline, findings were discrepant. Significant hippo-
campal atrophy has been reported in amyloid-positive cases in
some studies (Hedden et al., 2009; Storandt et al., 2009), but not in
others (Bourgeat et al., 2010; Dickerson et al., 2009), and temporal
pole (Dickerson et al., 2009) or anterior and posterior cingulate cor-
tex (Becker et al., 2011; Storandt et al., 2009) and prefrontal and
lateral parietal cortex (Becker et al., 2011) atrophy or thickness re-
duction has been reported as well. When assessed linearly, a significant
correlation has been found between global 11C-PIB and hippocampal
atrophy in normal elderly (Mormino et al., 2009; Rowe et al., 2010),
thought negative findings have been reported as well (Becker et al.,
2011). Finally, a recent study reports a covariation between increase
global 11C-PIB and decrease gray matter volume including in the medial
and lateral temporal lobe, andmedial frontal and posterior cingulate cor-
tex (Oh et al., in press).
As a whole, the relationships between cerebral Aβ deposits and con-
comitant cognitive performances or gray matter volume/thickness are
complex and subtle. This probably reflects the fact that, if Aβ deposition
361G. Chételat et al. / NeuroImage: Clinical 2 (2013) 356–365has a role in neurodegeneration and cognitive deficits, it is probably indi-
rect and/or blurred by the time decay between the different biomarkers
(Jack et al., 2010), and/or by the intervention of other probably partly in-
dependent factors (e.g. tau-related changes, decreased metabolism,
whitematter abnormalities and disconnection, cognitive and brain com-
pensation, etc.). There are accumulating evidences that Alzheimer's dis-
ease is a multifactorial disease with different and partly independent
subtending processes rather than a single-process-driven pathology
(Chételat et al., 2008; La Joie et al., 2012; Storandt et al., 2012); see
http://www.alzforum.org/res/for/journal/detail.asp?liveID=199 for
a live discussion on this topic.
3.2. Relation to prognosis — later changes in clinical status, cognition or
brain volume
Longitudinal studies assessing the relationships between base-
line Aβ deposition and subsequent changes in cognition or brain vol-
ume usually report that the presence of Aβ deposition in the brain of
cognitively normal elderly is associated with a worse prognosis.
Thus, Villemagne et al. (2011) showed that 5 out of 32 (16%) of the
11C-PIB-positive cognitively normal elderly developed MCI or AD
by 20 months and 8 out of 32 (25%) by 3 years while only one out
of 73 11C-PIB-negative normal elderly developed MCI. Also, elevated
Aβ deposition in cognitively normal elderly was shown to be related
to greater clinical worsening (based on the CDR and/or ADAS-Cog
scales) (Doraiswamy et al., 2012; Morris et al., 2009) and cognitive
decline (in episodic and working memory and visuospatial ability)
(Resnick et al., 2010; Storandt et al., 2009). In Doraiswamy et al.
(2012), 23.5% of CDR0 amyloid-positive cognitively normal elderly
converted to CDR0.5 within 18 months versus 5.5% within the
amyloid-negative elderly. Finally, one longitudinal MRI study
showed that 11C-PIB-positive cognitively normal elderly exhibited
faster gray matter atrophy compared to 11C-PIB-negative cases at a
group level (Chételat et al., 2012). Moreover, the amount of neocor-
tical Aβ deposition correlated with the rate of subsequent atrophy
in AD-sensitive brain areas (i.e. the temporal neocortex, hippocam-
pus, posterior cingulate cortex, and angular gyrus), which was itself
related to the rate of subsequent cognitive decline. These findings
are consistent with a preliminary report in 13 healthy controls by
Scheinin et al. (2009) or with findings in patients with MCI (Tosun
et al., 2011a) (see the side article by Vandenberghe (2013–this
issue)), as well as with studies showing that low CSF Aβwas associ-
ated with a faster rate of atrophy in similar AD-sensitive brain areas
(Hua et al., 2010; Leow et al., 2009; Schott et al., 2010; Tosun et al.,
2011b). It should be noted however that the findings in cognitively
normal elderly should be considered carefully, keeping in mind that
they were mostly obtained in community-recruited cohort studies
where selection biases may be present, which may have an influ-
ence not only on the rate of amyloid-positive cases as discussed
above, but also on the rate of conversion to AD and on the interaction
between both factors (i.e. on the rate of conversion to AD of the amyloid-
positive elderly). Consistent with this statement, the rate of conversion
to AD in amyloid PET studies is usually particularly elevated, more than
what would be expected given the incidence reported in the general
population (see e.g. Whitwell et al., 2012). Although this questions
the absolute number of converters within the amyloid-positives,
these findings as a whole indicate that, on average, the prognosis
in a group of individuals having Aβ in the brain, even if they are
asymptomatic, is worse than that of a group of individuals
with no Aβ.
4. The new research criteria for preclinical AD
The considerable advances in neuroimaging and cerebrospinal bio-
markers for AD in the last two decades, with amyloid imaging being
the most recent and certainly the most notable of these developments,led to the revision of the NINCDS-ADRDA clinical diagnosis criteria for
AD (McKhann et al., 1984). Several propositions have been published
by different groups and addressing different clinical populations
(Albert et al., 2011; Dubois et al., 2007; Dubois et al., 2010; McKhann
et al., 2011; Sperling et al., 2011), and the present review will focus on
the recommendation for the preclinical stages of AD (Sperling et al.,
2011). These new criteria also take into account the hypothetical
model of the chronology of the different biomarkers (Jack et al., 2010)
itself largely based on the amyloid cascade hypothesis (Hardy and
Selkoe, 2002), and consistently propose three stages in the preclinical
phase: Aβ is present in the first stage without neuronal injury (stage 1),
then neuronal injury is detected as well (stage 2), and then subtle cogni-
tive decline appears (stage 3). When assessed in a population-based
sample of 450 CNE, 43% of individuals were negative for the 3 biomarkers
so theywere considered as stage 0, and16%were in stage 1, 12% in stage 2
and 3% in stage 3 (Jack et al., 2012). In addition, another category had to
be added to account for the whole population, as 23% of subjects didn't
fit into any group because they had AD-type neuronal injury (i.e. hippo-
campal atrophy and/or hypometabolism in the angular gyrus, posterior
cingulate and inferior temporal cortex) without evidence of Aβ deposi-
tion. As this doesn't fit with the biomarkers chronology model that
predicts that Aβ appears before neurodegeneration, these individuals
were suspected to have non-AD pathology and were called as SNAP (for
Suspected Non-Alzheimer's disease Pathophysiology). Longitudinal
studies with a clinical follow-up of individuals in the different stages/
categories are extremely important in the current context to confirm
this view but also more generally to validate the diagnosis criteria and
current dynamic biomarker models and further our understanding of
the mechanisms underlying the disease. Actually, a recent publication
provides first insights to these questions by showing the clinical out-
come of participants according to each stage (Knopman et al., 2012).
This study showed that the more positive biomarkers you have the
more likely you are to convert, which confirms the usefulness of these
biomarkers. It didn't allow to validate the chronology of biomarkers
proposed by themodel however, as the rate of conversion toMCI or de-
mentia was similar in individuals in stage 1, i.e. who only had Aβ depo-
sition in their brain (11%) as compared to the SNAP subjects, i.e. those
having only neuronal injury but no Aβ (10%). This 10% conversion rate
within the SNAP group was thus striking, but could still reflect the fact
that they have non-AD related pathologies such as cerebrovascular dis-
ease. A recent publication however reveals that these so-called SNAP
caseswere indistinguishable from preclinical AD stages 1–3 on a variety
of measures including those associated with the most frequent non-AD
pathophysiological processes, i.e. cerebrovascular disease and α-
synucleinopathy (Knopman et al., in press). The authors concluded
that the initial appearance of brain injury biomarkers in cognitively nor-
mal elderly individuals may not depend on β-amyloidosis, which thus
contradicts both the chronology proposed in the currently prevailing
model and the amyloid cascade hypothesis. This, together with other
arguments (e.g. Chételat, 2013; Fjell and Walhovd, 2012; Herrup,
2011) will probably further motivate researchers to consider alterna-
tives to the amyloid hypothesis where Aβ promotes but is not necessar-
ily responsible for, AD-related neurodegeneration (Chételat, 2013).
5. Longitudinal amyloid imaging
As a whole, except in the first studies where sample sizes were rel-
atively small and changes were not statistically significant (Jagust
et al., 2010; Scheinin et al., 2009), longitudinal amyloid imaging stud-
ies showed significant increase in Aβ load in cognitively normal el-
derly of about 1% per year (Jack et al., 2009; Sojkova et al., 2011;
Villain et al., 2012; Villemagne et al., 2011; Vlassenko et al., 2011).
This increase was found to be higher in amyloid-positive than in neg-
ative cognitively normal elderly, and lower in cognitively normal el-
derly compared to MCI or AD though this was due to the fact that
there were more amyloid-negative cases within the cognitively
Table 2
Advantages and disadvantages of disclosing the result of an amyloid-scan to cognitively
normal elderly.
Advantages Disadvantages
A correct diagnosis may be clarifying
and appreciated by the patient and
his/her relatives
The result of AD biomarker testing is
potentially harmful, especially absent
an effective disease-modifying
treatment for AD (>55 yrs fear AD
more than any other disease
including cancer)
Opportunity to reduce suffering and costs
for both patients and society
Problems related to inconclusive scans
(uncertainty, reproducibility and
accuracy)
Enables early decision making when
patients still have full decision
competence + help in receiving
assistance to cope with progressive
decline + from health care system
Risks of stigmatization, feeling of
hopelessness, agony and despair,
anxiety, depression, increase of suicide
attempts and euthanasia request
(Draper et al., 2010)
Possibility to take even unproven
intervention in an effort to reduce the
risk: a positive scan might encourage
lifestyle changes (diet, exercise,
cognitive training, etc.) even if effects
are modest at best
Risks of affecting insurance premiums,
right to drive, work conditions
Relief related to a negative amyloid
imaging scan
Ethical consequences of false diagnosis
could be serious
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for the 11C-PIB status, no difference was found in the rate of 11C-PIB
accumulation between clinical groups (Villain et al., 2012). Most sig-
nificant changes were observed in prefrontal, parietal, lateral tempo-
ral and occipital cortex (Sojkova et al., 2011; Villain et al., 2012) and
anterior and posterior cingulate cortex (Sojkova et al., 2011). Increase
in 11C-PIB over time in amyloid-negative cognitively normal elderly
was found to be lower than in amyloid-positive but still significant.
Individual analyses showed that there were more 11C-PIB accumula-
tors (i.e. individuals showing significant 11C-PIB accumulation/
increase over time) amongst 11C-PIB-positive (50%) than amongst
11C-PIB-negative (29%) cognitively normal elderly (Villain et al.,
2012). The incidence of conversion from negative to positive within
cognitively normal elderly was about 3% per year, and raised 7% in
the ApoE4 carriers (Vlassenko et al., 2011). The rate of 11C-PIB accu-
mulation remains higher in the 11C-PIB-positive cases when only con-
sidering the accumulators, suggesting that those with higher 11C-PIB
have greater rate of 11C-PIB accumulation, while this trend tends to
reverse in those with high baseline 11C-PIB retention, consistent
with the concept of a saturable process of Aβ deposition as
the 11C-PIB retention reaches highest values (Villain et al., 2012). Fur-
ther discussion on the dynamic of Aβ all over the course of the disease
including in clinical stages will be provided in the side review by
Vandenberghe (2013–this issue).
6. Ethical considerations
The progressive discovery of biomarkers for AD that peaks with am-
yloid neuroimaging, their use in the newproposed criteria for AD includ-
ing specifically for preclinical AD, the recent approval of Amyvid
(florbetapir F18 injection) by the FDA on April 9th 2012, altogether re-
vive the debate on ethical challenges of preclinical AD that has been
already, at least partly, addressed with the development of ApoE
genotyping and predictive genetic testing. There have been an increasing
interest in this question recently, and several groups develop specific
studies and publish reviews fully-dedicated to this issue (Blennow and
Zetterberg, 2010; Draper et al., 2010; Karlawish, 2011; Mattsson et al.,
2010; Prvulovic and Hampel, 2011; Roberts and Tersegno, 2010). The
present review was not aimed at providing a detailed overview on ethi-
cal and social issues associatedwith preclinical AD. However, inspired by
these authors, the main questions will be highlighted as they are crucial
when dealing with amyloid imaging in preclinical populations.
Thus, early diagnosis in general, amyloid imaging in preclinical
population in particular, raises important ethical issues as regard to
disclosure of these information to individuals. There is a distinction
between clinical assessments versus research. Researchers have no
obligation to disclose biomarker results to participants, and the in-
formed consent explains to them why they will not be given such in-
formation (Karlawish, 2011). As for the clinic, we are far from a
routine use in clinical practice for the preclinical diagnosis for AD:
amyloid imaging doesn't fulfill the requirements for a screening test
(in terms of cost, accuracy, availability, etc) according to the princi-
ples and practice of screening for disease published by the World
Health Organization (Wilson, 1968). FDA approval is only for cogni-
tively impaired patients, and the use of biomarkers in preclinical AD
is only for research. However, scientists and clinicians should prepare
to face the problem, notably to anticipate the hopeful future develop-
ment of disease-modifying treatments.
While it is quite clear that there are amyloid-positive cases amongst
cognitively normal elderly, and that their risk of conversion to AD is
probably higher than for amyloid-negative cognitively normal elderly,
it is also clear that not all amyloid-positive cognitively normal elderly
will convert to AD at least in the following couple of years. Thus, the
rate of conversion to MCI/AD in amyloid-positive cognitively normal
elderly is about 15–25% within the following 2–3 years (see above),
which means that about 80% will remain stable over this period. TheAIBL study offers one of the largest database with amyloid PET
imaging and with the longest follow-up time, and it shows that
some 11C-PIB-positive cognitively normal elderly remain cognitively sta-
ble even after a 6 year follow-up (Rowe and Villemagne, personal com-
munication). This leads to the first following question: is it ethical to
deliver an amyloid-scan result while not all amyloid-positive individuals
will develop AD. This means that what is delivered is not diagnosis but
risk information. This distinction is very important as it should be per-
fectly clear, for the clinician of course but also for the patient and his
family, that what is disclosed from an amyloid scan is information
about the presence of Aβ deposition in the brain, associated with a
risk to develop AD, but not on the diagnosis of AD itself. This is thus
the same situation as for disclosing ApoE genotype and scientists thus
take their inspiration from the relatively abundant literacy on disclosing
genetic information. This leads to a second question that more generally
applies to early AD diagnosis: is it ethical to deliver the risk information
related to an amyloid-scan result while there is no treatment? The
growing distance between scientific advances in terms of diagnosis ver-
sus treatment and the uncoupling between the diagnosis and the clinical
expression of the disease also raise ethical issues. When trying to
answer to these questions, one should also take into account patient's
right to know and find the balance between the patient's desire to
know his risk developing AD and the clinician's desire to mitigate the
potential harm of that information. These are very difficult questions
to answer, as of course there are both advantages and disadvantages
in disclosing risk information such as the results of an amyloid scan in
asymptomatic individuals and in preclinical AD diagnosis (see Table 2
for examples of advantages and disadvantages).
Our advances in terms of preclinical diagnosis and biomarkers
should thus be paralleled by evidence-based advances in our knowl-
edge on the way to disclose this information and on its psychological
implications, as well as by societal and legislative evolution. More
specifically, studies are needed (and are currently under progress)
to track the emotional and physical impact of the disclosure, and to
develop and disseminate best practice guide on how to disclose the
result of an amyloid scan. Again, such procedures have already been
defined for disclosure of genetic information (such as providing time
for reflection prior to disclosing results, psychological support, delivery
363G. Chételat et al. / NeuroImage: Clinical 2 (2013) 356–365in a face-to-face meeting, etc) that provide a significant basis for adap-
tation to the case of amyloid imaging in preclinical populations.
We cannot work on amyloid imaging in preclinical AD without an-
ticipating the related ethical challenges. Clearly, we are not ready yet
for the diagnosis of preclinical AD. There are numerous challenges
that should first be faced, several essential questions of ethical impli-
cations that still need to be answered; our knowledge on how pa-
tients actually react to early diagnosis is still too scarce and
preliminary steps are thus needed to translate research results into
clinical practice and policy.7. Conclusion
As a whole, there are evidences for which there is absolutely no
doubt on: some cognitively normal elderly have Aβ deposition in their
brain, the prevalence of amyloid-positive cases increases in at-risk pop-
ulations, the prognosis for these individuals (as a group) is worse than
for those with no Aβ deposition, and significant increase in Aβ deposi-
tion over time is detectable in cognitively normal elderly. Other points
are more obscure: the relation between Aβ deposition and AD-related
changes (cognition, atrophy, hypometabolism and connectivity) is
complex, the sequence and cause-to-effect relationships between the
different biomarkers are challenged, and the individual outcome associ-
ated with an amyloid-positive scan is still unknown: will all amyloid-
positive elderly eventually develop AD and when? Further studies are
needed to know how to translate group findings into individual use,
i.e. how to use amyloid imaging to support AD diagnosis in preclinical
individuals. Preclinical amyloid imaging also raises important ethical is-
sues. There is a distinction between clinic and research for the use of
amyloid imaging, and between clinicians and researchers for the disclo-
sure of information. Amyloid imaging is definitively useful to under-
stand the role of Aβ in early stages, to define at-risk populations for
research or for clinical trial, and to assess the effects of anti-amyloid
treatments. However, we are not ready yet to translate research results
into clinical practice and policy. The considerable advances of research
in terms of amyloid imaging, biomarkers and preclinical diagnosis
over the last decade should be paralleled by significant progress in our
knowledge on the way of disclosing such information and its impact,
as well as societal and legislation adaptation to anticipate the future
where preclinical diagnosis and disease-modifying treatment will
hopefully be available.Acknowledgments
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